PROCESS FOR PRODUCING FOREIGN PROTEIN IN ESCHERICHIA COLI
    21.
    发明公开
    PROCESS FOR PRODUCING FOREIGN PROTEIN IN ESCHERICHIA COLI 有权
    过程在大肠杆菌中产生杂质蛋白

    公开(公告)号:EP1602720A4

    公开(公告)日:2008-06-18

    申请号:EP04713206

    申请日:2004-02-20

    摘要: It is intended to provide a foreign protein free from any expression inducer and a process for producing the same. Namely, a process for producing a foreign protein involving the step of proliferating a recombinant Escherichia coli, which expresses the foreign protein under the control by a promoter capable of inducing the expression due to the temperature shift, by arbitrarily culturing at a low temperature and then culturing the strain at a high temperature in the absence of an expression inducer to thereby allow the expression of the foreign protein, or the step of culturing the above Escherichia coli strain at a high temperature and thus effecting the proliferation of the cells and the expression of the foreign protein at the same time; and a foreign protein free from any expression inducer which is obtained by this process. Particular examples of such foreign proteins include main tick allergens, Actinogacillus pleuropneumoniae-origin secretory macrophage toxin and a protective antigen against Erysipelothrix rhusiopathiae-infection.

    ANTI-HIV MONOCLONAL ANTIBODY
    26.
    发明公开
    ANTI-HIV MONOCLONAL ANTIBODY 失效
    单克隆抗HIV抗体

    公开(公告)号:EP0690132A4

    公开(公告)日:1998-07-29

    申请号:EP94909286

    申请日:1994-03-09

    摘要: The invention provides a clinically useful monoclonal antibody which can recognize the conserved region of the V3-PND region of a glycoprotein antigen (gp120) having a molecular weight of about 120,000 Da and contained in the coat of a human immunodefiency virus (HIV) and which can neutralize a wide variety of HIV variants, or a fragment of the above antibody, and chimera and humanized antibodies derived from the above antibody. It is possible to prepare a monoclonal antibody having the activity of neutralizing various HIV variants by using as the immunogen several types of peptides having a PND tip region containing a GPGR sequence having a high conservability in the PND region of the gp120 of an HIV. It is possible to obtain a chimera antibody or an altered antibody having an anti-HIV neutralization activity effective for clinical application by transplanting a fragment of a gene coding for the variable region of the above monoclonal antibody or the complementarity-determining region of that region to a human antibody gene.